COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
OSE Immunotherapeutics annonce la présentation des résultats de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire au Congrès 2026 de l’ASCO
OSE Immunotherapeutics annonce la présentation des résultats de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire au Congrès 2026 de l’ASCO. Présentation orale le 30 mai 2026, à Chicago, Etats-Unis -
COMMUNIQUÉ DE PRESSE
OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
OSE Immunotherapeutics announces topline results from TEDOVA Phase 2 trial of Tedopi® in Ovarian Cancer at ASCO 2026 Meeting. Presentation by lead investigator Alexandra Leary, MD, PhD -
COMMUNIQUÉ DE PRESSE
Helvetia Baloise successfully places three senior bond tranches totalling CHF 550 million
Helvetia Baloise successfully places three senior bond tranches totalling CHF 550 million on Swiss capital market. Proceeds for corporate purposes & potential refinancing. Strong investor demand -
-
COMMUNIQUÉ DE PRESSE
Sartorius Stedim Biotech reports robust first-quarter results for fiscal 2026
Sartorius Stedim Biotech reports robust first-quarter results for fiscal 2026 with sales revenue up 7.9% in constant currencies. Profitability remains strong with a margin of 30.7% and net profit of 88 million euros -
-
-
